167 related articles for article (PubMed ID: 37731205)
1. The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer.
Wang X; Qiu W; Liu H; He M; He W; Li Z; Wu Z; Xu X; Chen P
Cancer Biol Med; 2023 Sep; 20(9):662-81. PubMed ID: 37731205
[TBL] [Abstract][Full Text] [Related]
2. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.
Burdelya LG; Brackett CM; Kojouharov B; Gitlin II; Leonova KI; Gleiberman AS; Aygun-Sunar S; Veith J; Johnson C; Haderski GJ; Stanhope-Baker P; Allamaneni S; Skitzki J; Zeng M; Martsen E; Medvedev A; Scheblyakov D; Artemicheva NM; Logunov DY; Gintsburg AL; Naroditsky BS; Makarov SS; Gudkov AV
Proc Natl Acad Sci U S A; 2013 May; 110(20):E1857-66. PubMed ID: 23630282
[TBL] [Abstract][Full Text] [Related]
3. [Construction of NKG2D CAR-NK92 cells and its killing effect on multiple myeloma cells].
Long J; Zheng R; Ye S; Ke S; Duan D; Wei C; Gao J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Jul; 39(7):577-585. PubMed ID: 37403715
[TBL] [Abstract][Full Text] [Related]
4. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity.
Leigh ND; Bian G; Ding X; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
PLoS One; 2014; 9(1):e85587. PubMed ID: 24454895
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 5 agonist CBLB502 induces radioprotective effects in vitro.
Shi T; Li L; Zhou G; Wang C; Chen X; Zhang R; Xu J; Lu X; Jiang H; Chen J
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):487-495. PubMed ID: 28407032
[TBL] [Abstract][Full Text] [Related]
6. A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease.
Ding X; Bian G; Leigh ND; Qiu J; McCarthy PL; Liu H; Aygun-Sunar S; Burdelya LG; Gudkov AV; Cao X
J Immunol; 2012 Nov; 189(10):4719-27. PubMed ID: 23045613
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 5-mediated signaling enhances liver regeneration in mice.
Zhang W; Wang L; Sun XH; Liu X; Xiao Y; Zhang J; Wang T; Chen H; Zhan YQ; Yu M; Ge CH; Li CY; Ren GM; Yin RH; Yang XM
Mil Med Res; 2021 Feb; 8(1):16. PubMed ID: 33622404
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 5 signaling restrains T-cell/natural killer T-cell activation and protects against concanavalin A-induced hepatic injury.
Wang L; Zhang W; Ge CH; Yin RH; Xiao Y; Zhan YQ; Yu M; Li CY; Ge ZQ; Yang XM
Hepatology; 2017 Jun; 65(6):2059-2073. PubMed ID: 28273362
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy.
Burdelya LG; Gleiberman AS; Toshkov I; Aygun-Sunar S; Bapardekar M; Manderscheid-Kern P; Bellnier D; Krivokrysenko VI; Feinstein E; Gudkov AV
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):228-34. PubMed ID: 22000579
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner.
Zhou SX; Li FS; Qiao YL; Zhang XQ; Wang ZD
Asian Pac J Cancer Prev; 2012; 13(6):2807-12. PubMed ID: 22938463
[TBL] [Abstract][Full Text] [Related]
11. Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells.
Luo H; Wu X; Sun R; Su J; Wang Y; Dong Y; Shi B; Sun Y; Jiang H; Li Z
Front Oncol; 2019; 9():1448. PubMed ID: 31921693
[TBL] [Abstract][Full Text] [Related]
12. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis.
Lu C; Guo C; Chen H; Zhang H; Zhi L; Lv T; Li M; Niu Z; Lu P; Zhu W
Mol Immunol; 2020 May; 122():200-206. PubMed ID: 32388482
[TBL] [Abstract][Full Text] [Related]
13. Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.
Klapdor R; Wang S; Hacker U; Büning H; Morgan M; Dörk T; Hillemanns P; Schambach A
Hum Gene Ther; 2017 Oct; 28(10):886-896. PubMed ID: 28836469
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer.
Rhee SH; Im E; Pothoulakis C
Gastroenterology; 2008 Aug; 135(2):518-28. PubMed ID: 18538140
[TBL] [Abstract][Full Text] [Related]
15. Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells.
Liu H; Yang B; Sun T; Lin L; Hu Y; Deng M; Yang J; Liu T; Li J; Sun S; Jiao S
Oncol Rep; 2015 Jan; 33(1):95-102. PubMed ID: 25333815
[TBL] [Abstract][Full Text] [Related]
16. CBLB502, an agonist of Toll-like receptor 5, has antioxidant and scavenging free radicals activities in vitro.
Li W; Ge C; Yang L; Wang R; Lu Y; Gao Y; Li Z; Wu Y; Zheng X; Wang Z; Zhang C
Int J Biol Macromol; 2016 Jan; 82():97-103. PubMed ID: 26476243
[TBL] [Abstract][Full Text] [Related]
17. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
[TBL] [Abstract][Full Text] [Related]
18. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells].
Qu Y; Bi JZ
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(11):860-866. PubMed ID: 29609271
[No Abstract] [Full Text] [Related]
19. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
[TBL] [Abstract][Full Text] [Related]
20. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
